Staff Members - Benha University
Soluble Receptor for Advanced Glycation End Products: a new biomarker in diagnosis of Diabetic Nephropathy
Life Science Journal 2012;9(4) • 2012
Publication Information
Authors
Hesham A. Issa1, Osama S. Elshaer1, Ahmed M. Awadallah1 and Tawfik El-Adl2.
Clinical and Chemical Pathology Department1 and Internal Medicine Department2, Faculty of Medicine, Benha
University, Benha, Egypt.
Keywords
sRAGE, diabetic nephropathy, microalbuminuria.
Journal
Life Science Journal 2012;9(4)
Publisher
Hesham A. Issa
Volume
9
Issue
4
Pages
7
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Abstract: Background: Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria (>300
mg/d or >200 mcg/min). The interaction of advanced glycation end products with their cellular receptor (RAGE) is
implicated in the pathogenesis of diabetic vascular complications. RAGE has a circulating secretory receptor form,
soluble RAGE (sRAGE), which, by neutralizing the action of advanced glycation end products, might exert a
protective role against the development of cardiovascular disease. Objective: to study the serum levels of sRAGE in
type 2 diabetic patients and to clarify the possible association with urinary albumin excretion as an early marker of
microvascular damage. Patients and Methods: Eighty subjects divided into two groups; group I (patients group)
included 60 type 2 diabetic patients. They were subdivided into 2 subgroups: twenty normo-albuminuric diabetic
subgroup and forty micro-albuminuric diabetic subgroup. Group II (control group) included 20 apparently healthy
individuals of matched age and sex. All cases were subjected for estimation of sRAGE by sandwich ELISA
technique together with routine laboratory investigations including fasting blood glucose, s. creatinine, cholesterol,
triglycerides, HDL-C, LDL-C, HbA1C and Microalbumin. Results: sRAGE was significantly lower in
microalbuminuric diabetic than normoalbuminuric diabetic and control groups (p
mg/d or >200 mcg/min). The interaction of advanced glycation end products with their cellular receptor (RAGE) is
implicated in the pathogenesis of diabetic vascular complications. RAGE has a circulating secretory receptor form,
soluble RAGE (sRAGE), which, by neutralizing the action of advanced glycation end products, might exert a
protective role against the development of cardiovascular disease. Objective: to study the serum levels of sRAGE in
type 2 diabetic patients and to clarify the possible association with urinary albumin excretion as an early marker of
microvascular damage. Patients and Methods: Eighty subjects divided into two groups; group I (patients group)
included 60 type 2 diabetic patients. They were subdivided into 2 subgroups: twenty normo-albuminuric diabetic
subgroup and forty micro-albuminuric diabetic subgroup. Group II (control group) included 20 apparently healthy
individuals of matched age and sex. All cases were subjected for estimation of sRAGE by sandwich ELISA
technique together with routine laboratory investigations including fasting blood glucose, s. creatinine, cholesterol,
triglycerides, HDL-C, LDL-C, HbA1C and Microalbumin. Results: sRAGE was significantly lower in
microalbuminuric diabetic than normoalbuminuric diabetic and control groups (p